Alpha1-antitrypsin ameliorates islet amyloid-induced glucose intolerance and β-cell dysfunction.


Journal

Molecular metabolism
ISSN: 2212-8778
Titre abrégé: Mol Metab
Pays: Germany
ID NLM: 101605730

Informations de publication

Date de publication:
07 2020
Historique:
received: 12 03 2020
accepted: 21 03 2020
pubmed: 2 4 2020
medline: 7 7 2021
entrez: 2 4 2020
Statut: ppublish

Résumé

Pancreatic β-cell failure is central to the development and progression of type 2 diabetes (T2D). The aggregation of human islet amyloid polypeptide (hIAPP) has been associated with pancreatic islet inflammation and dysfunction in T2D. Alpha1-antitrypsin (AAT) is a circulating protease inhibitor with anti-inflammatory properties. Here, we sought to investigate the potential therapeutic effect of AAT treatment in a mouse model characterized by hIAPP overexpression in pancreatic β-cells. Mice overexpressing hIAPP (hIAPP-Tg) in pancreatic β-cells were used as a model of amyloid-induced β-cell dysfunction. Glucose homeostasis was evaluated by glucose tolerance tests and insulin secretion assays. Apoptosis and amyloid formation was assessed in hIAPP-Tg mouse islets cultured at high glucose levels. Dissociated islet cells were cocultured with macrophages obtained from the peritoneal cavity. Nontreated hIAPP-Tg mice were glucose intolerant and exhibited impaired insulin secretion. Interestingly, AAT treatment improved glucose tolerance and restored the insulin secretory response to glucose in hIAPP-Tg mice. Moreover, AAT administration normalized the expression of the essential β-cell genes MafA and Pdx1, which were downregulated in pancreatic islets from hIAPP-Tg mice. AAT prevented the formation of amyloid deposits and apoptosis in hIAPP-Tg islets cultured at high glucose concentrations. Since islet macrophages mediate hIAPP-induced β-cell dysfunction, we investigated the effect of AAT in cocultures of macrophages and islet cells. AAT prevented hIAPP-induced β-cell apoptosis in these cocultures without reducing the hIAPP-induced secretion of IL-1β by macrophages. Remarkably, AAT protected β-cells against the cytotoxic effects of conditioned medium from hIAPP-treated macrophages. Similarly, AAT also abrogated the cytotoxic effects of exogenous proinflammatory cytokines on pancreatic β-cells. These results demonstrate that treatment with AAT improves glucose homeostasis in mice overexpressing hIAPP and protects pancreatic β-cells from the cytotoxic actions of hIAPP mediated by macrophages. These results support the use of AAT-based therapies to recover pancreatic β-cell function for the treatment of T2D.

Identifiants

pubmed: 32229246
pii: S2212-8778(20)30058-2
doi: 10.1016/j.molmet.2020.100984
pmc: PMC7186564
pii:
doi:

Substances chimiques

Amyloid 0
Blood Glucose 0
Insulin 0
Islet Amyloid Polypeptide 0
alpha 1-Antitrypsin 0
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100984

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier GmbH.. All rights reserved.

Références

Nat Immunol. 2010 Oct;11(10):897-904
pubmed: 20835230
Cell Rep. 2018 Feb 13;22(7):1774-1786
pubmed: 29444430
Diabetologia. 2014 Sep;57(9):1884-8
pubmed: 24965964
Diabetologia. 2001 Dec;44(12):2115-33
pubmed: 11793013
J Clin Invest. 2002 Sep;110(6):851-60
pubmed: 12235117
Endocr Rev. 2008 May;29(3):303-16
pubmed: 18314421
Cell Metab. 2013 Apr 2;17(4):534-48
pubmed: 23562077
Cell Mol Immunol. 2014 Jul;11(4):377-86
pubmed: 25000533
Amyloid. 2014 Sep;21(3):191-201
pubmed: 25007035
Mol Metab. 2018 Aug;14:95-107
pubmed: 29914854
J Biol Chem. 2003 Dec 26;278(52):52810-9
pubmed: 14532296
J Clin Invest. 2014 Aug;124(8):3634-44
pubmed: 25036706
Diabetes. 2014 May;63(5):1698-711
pubmed: 24222351
Diabetes Metab. 2013 Dec;39(6):524-31
pubmed: 24075453
Nat Immunol. 2017 Mar;18(3):283-292
pubmed: 28092375
JCI Insight. 2016 Apr 07;1(4):e86055
pubmed: 27699257
Diabetes. 2007 Sep;56(9):2284-94
pubmed: 17563070
Diabetologia. 2015 Mar;58(3):575-85
pubmed: 25491100
Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1317-24
pubmed: 16849627
Diabetologia. 2012 Jan;55(1):166-74
pubmed: 22038516
Biologics. 2009;3:193-204
pubmed: 19707408
Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16236-41
pubmed: 18852465
Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15007-12
pubmed: 23975926
Sci Rep. 2017 Jul 24;7(1):6285
pubmed: 28740254
Diabetes. 2001 May;50(5):909-20
pubmed: 11334433
Diabetologia. 2007 Mar;50(3):602-11
pubmed: 17221214
Diabetes. 2003 Sep;52(9):2304-14
pubmed: 12941770
Diabetes. 2017 Dec;66(12):3029-3040
pubmed: 28970284
N Engl J Med. 2007 Apr 12;356(15):1517-26
pubmed: 17429083
Diabetologia. 2013 Aug;56(8):1761-72
pubmed: 23685457
Diabetes Obes Metab. 2017 May;19(5):682-694
pubmed: 28058779
Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12153-8
pubmed: 16093309
J Immunol. 2011 Sep 1;187(5):2755-65
pubmed: 21813778
Mol Metab. 2017 May 31;6(8):833-844
pubmed: 28752047
Trends Mol Med. 2015 Jul;21(7):439-49
pubmed: 25998900
Diabetes. 2017 Apr;66(4):970-980
pubmed: 28069642
Nat Med. 2012 Sep;18(9):1407-12
pubmed: 22863787
Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16242-7
pubmed: 18852471
Diabetes. 2017 Oct;66(10):2636-2645
pubmed: 28729244
Am J Respir Crit Care Med. 2006 Jun 1;173(11):1222-8
pubmed: 16514110
FASEB J. 2017 Dec;31(12):5296-5306
pubmed: 28821639
Diabetes. 1990 May;39(5):634-8
pubmed: 2185112
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13998-4003
pubmed: 19666548
Biochem Biophys Res Commun. 2004 Aug 27;321(3):592-600
pubmed: 15358147
Diabetes. 2007 May;56(5):1316-23
pubmed: 17360983
Am J Pathol. 2011 Jun;178(6):2632-40
pubmed: 21641386

Auteurs

Júlia Rodríguez-Comas (J)

Diabetes and Obesity Research Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Juan Moreno-Vedia (J)

Diabetes and Obesity Research Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Mercè Obach (M)

Diabetes and Obesity Research Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Carlos Castaño (C)

Diabetes and Obesity Research Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain.

Sara de Pablo (S)

Diabetes and Obesity Research Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Gema Alcarraz-Vizán (G)

Diabetes and Obesity Research Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain.

Daniela Díaz-Catalán (D)

Diabetes and Obesity Research Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain.

Anna Mestre (A)

Grifols Bioscience Research Group, Barcelona, Spain.

Raquel Horrillo (R)

Grifols Bioscience Research Group, Barcelona, Spain.

Montserrat Costa (M)

Grifols Bioscience Research Group, Barcelona, Spain.

Anna Novials (A)

Diabetes and Obesity Research Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain. Electronic address: anovials@clinic.cat.

Joan-Marc Servitja (JM)

Diabetes and Obesity Research Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain. Electronic address: servitja@clinic.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH